Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study

• Algernon (AGN) has received positive feedback from the United Kingdom Medicines and Healthcare Products Regulatory Agency
• The feedback was related to the company’s planned Phase 1/2a stroke study with AP-188 (“N,N-dimethyltryptamine” or “DMT”)
• Algernon CEO Christopher Moreau sat down with Dave Jackson to discuss the feedback and the company’s future plans for DMT
• The company plans to file a Clinical Trial Authorisation (CTA) application for the study as soon as possible
• Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
• Algernon Pharmaceuticals Inc. (AGN) is down 9.09 per cent on the day, trading at C$0.05 per share at 1pm ET

Algernon (AGN) received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.

The feedback was related to the company’s planned Phase 1/2a stroke study with AP-188 (“N,N-dimethyltryptamine” or “DMT”), a known psychedelic compound that is part of the tryptamine family.

Algernon CEO Christopher Moreau sat down with Dave Jackson to discuss the feedback and the company’s future plans for DMT.

“We were very encouraged by today’s meeting with the UK MHRA. The feedback we received was very helpful and we look forward to working with the agency as we move forward with the important work of investigating DMT as a possible therapy for stroke patients globally.”

As a result of the meeting, the company plans to file a Clinical Trial Authorisation (CTA) application for the study as soon as possible. Based on the feedback received, Algernon is also considering focusing on DMT as a possible treatment for acute stroke for the Phase 2a part of the study, in addition to investigating DMT as an adjunctive treatment for stroke rehabilitation therapy.

The company is planning to conduct the Phase 1 part of the study at Hammersmith Medicines Research in London, UK and is now targeting to begin the study in January 2022.

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds.

Algernon Pharmaceuticals Inc. (AGN) is down 9.09 per cent on the day, trading at C$0.05 per share at 1pm ET.